Once-a-day (QD) vs twice-daily (BID) nevirapine as simplification in PI-treated patients after 2 mos. of BID induction

Renato Maserati, Micaela Brandolini, Annamaria Cattelan, Anna Orani, Laura Sighinolfi, Massimo Andreoni, Alessia Uglietti, Giovanni Guaraldi, Giovanni Sotgiu

Research output: Contribution to journalArticlepeer-review

Abstract

To assess the efficacy and the tolerability of once-daily (QD) versus twice-daily (BID) nevirapine (NVP)-based highly active antiretroviral therapy (HAART) in virologically suppressed, HIV-positive patients switched from protease inhibitor (PI)-based HAART.Eligible patients were enrolled in the multicenter trial if HIV RNA levels were

Original languageEnglish
Pages (from-to)166-173
Number of pages8
JournalCurrent HIV Research
Volume9
Issue number3
DOIs
Publication statusPublished - Apr 2011

Keywords

  • Adverse events
  • Antiretroviral therapy
  • HIV
  • Nevirapine
  • Once-daily
  • Therapy switch

ASJC Scopus subject areas

  • Infectious Diseases
  • Virology

Fingerprint Dive into the research topics of 'Once-a-day (QD) vs twice-daily (BID) nevirapine as simplification in PI-treated patients after 2 mos. of BID induction'. Together they form a unique fingerprint.

Cite this